Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock: Insider Bros. Advisors Lp Baker Purchases 15,666 Shares

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Director Bros. Advisors Lp Baker acquired 15,666 shares of Madrigal Pharmaceuticals stock in a transaction on Wednesday, November 4th. The shares were purchased at an average price of $367.71 per share, with a total value of $5,760,544.86. Following the completion of the purchase, the director owned 1,964,542 shares in the company, valued at $722,381,738.82. This represents a 0.80% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Bros. Advisors Lp Baker also recently made the following trade(s):

• On Friday, November 6th, Bros. Advisors Lp Baker bought 76,140 shares of Madrigal Pharmaceuticals stock. The stock was purchased at an average price of $384.32 per share, for a total transaction of $29,262,124.80.

Madrigal Pharmaceuticals Stock Down 0.1%

Shares of MDGL traded down $0.47 on Friday, hitting $399.63. 1,087,445 shares of the stock traded hands, compared to its average volume of 352,856. The company has a market capitalization of $9.28 billion, a PE ratio of -66.83 and a beta of -0.98. The company has a debt-to-equity ratio of 0.54, a quick ratio of 2.94 and a current ratio of 3.05. The business has a 50 day simple moving average of $489.63 and a 200 day simple moving average of $497.94. Madrigal Pharmaceuticals, Inc. has a one year low of $353.54 and a one year high of $615.00.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last posted its earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $1.83 EPS for the quarter, topping analysts’ consensus estimates of ($1.09) by $2.92. The business had revenue of $431.27 million during the quarter, compared to analyst estimates of $404.17 million. Madrigal Pharmaceuticals had a negative return on equity of 27.08% and a negative net margin of 10.89%. During the same quarter last year, the company earned ($5.08) EPS. As a group, equities analysts forecast that Madrigal Pharmaceuticals, Inc. will post -6.88 earnings per share for the current fiscal year.

Analyst Ratings Changes

MDGL has been the subject of several research analyst reports. The Goldman Sachs Group assumed coverage on Madrigal Pharmaceuticals in a report on Thursday, September 24th. They issued a “buy” rating and a $704.00 price objective for the company. UBS Group restated a “buy” rating and set a $735.00 target price on shares of Madrigal Pharmaceuticals in a research note on Wednesday, October 14th. Truist Financial restated a “buy” rating and set a $743.00 target price (up from $709.00) on shares of Madrigal Pharmaceuticals in a research note on Wednesday. Citigroup raised their price target on shares of Madrigal Pharmaceuticals from $725.00 to $760.00 and gave the company a “buy” rating in a report on Tuesday. Finally, Wells Fargo & Company began coverage on shares of Madrigal Pharmaceuticals in a research note on Monday, July 27th. They issued an “overweight” rating and a $685.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $706.87.

More Madrigal Pharmaceuticals News

Here are the key news stories impacting Madrigal Pharmaceuticals this week:

• Positive Sentiment: Multiple real-world studies presented at AASLD reported improvements in liver stiffness and cardiometabolic health markers among patients treated with Rezdiffra, supporting the drug’s real-world potential. Rezdiffra real-world data
• Positive Sentiment: Madrigal’s latest quarterly results beat estimates: EPS was $1.83 versus consensus of a $1.09 loss, and revenue of $431.3 million exceeded the $404.2 million estimate. Madrigal stock jumps after earnings beat
• Positive Sentiment: HC Wainwright reiterated a Strong-Buy rating and projected rising EPS through 2030; Canaccord Genuity also raised its price target to $633 and maintained a Buy rating. These forecasts point to optimism about future growth, though they are analyst expectations, not guarantees.
• Neutral Sentiment: General Counsel Shannon Kelley sold 1,077 shares for about $430,800 under a pre-arranged Rule 10b5-1 plan. Kelley retained 10,397 shares, which may temper concern about the sale.
• Negative Sentiment: Several law firms announced investigations into potential securities-law violations after Madrigal’s November 3 quarterly filing. These are investigations and investor solicitations—not findings of wrongdoing—but could create legal and reputational uncertainty. Securities investigation announcement

Hedge Funds Weigh In On Madrigal Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. William Blair Investment Management LLC grew its holdings in shares of Madrigal Pharmaceuticals by 4.0% in the third quarter. William Blair Investment Management LLC now owns 337,035 shares of the biopharmaceutical company’s stock worth $169,852,000 after acquiring an additional 12,912 shares during the period. Russell Investments Group Ltd. increased its position in Madrigal Pharmaceuticals by 2.5% during the third quarter. Russell Investments Group Ltd. now owns 50,545 shares of the biopharmaceutical company’s stock valued at $25,473,000 after acquiring an additional 1,251 shares during the last quarter. Fifth Third Bancorp lifted its holdings in Madrigal Pharmaceuticals by 3.5% in the third quarter. Fifth Third Bancorp now owns 838 shares of the biopharmaceutical company’s stock valued at $422,000 after acquiring an additional 28 shares during the period. Maryland State Retirement & Pension System lifted its holdings in Madrigal Pharmaceuticals by 17.3% in the third quarter. Maryland State Retirement & Pension System now owns 1,098 shares of the biopharmaceutical company’s stock valued at $553,000 after acquiring an additional 162 shares during the period. Finally, Ritholtz Wealth Management bought a new position in Madrigal Pharmaceuticals in the third quarter valued at about $200,000. 98.50% of the stock is owned by institutional investors.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines for nonalcoholic steatohepatitis, now known as metabolic dysfunction-associated steatohepatitis (MASH), and other chronic liver diseases. The company is headquartered in West Conshohocken, Pennsylvania.

Madrigal’s lead product is Rezdiffra (resmetirom), an orally administered thyroid hormone receptor beta agonist designed to target key drivers of liver disease, including hepatic fat accumulation and fibrosis.